Oxford BioMedica, Microsoft Link Up on Gene Therapy Manufacturing

Oxford BioMedica PLC said Tuesday that it has entered a research collaboration with Microsoft to use cloud and machine-learning technology to improve gene and cell therapy manufacturing.

The U.K. company said it will work with Microsoft to improve the yield of purity of its lentiviral vectors, while driving down costs.

Lentiviral vectors deliver genetic information to cells and can be used in gene therapy.

Oxford BioMedica provides its lentiviral vectors to Novartis to use in its CAR-T cancer therapy, which was recently approved in the U.K.

https://www.marketscreener.com/OXFORD-BIOMEDICA-PLC-43524070/news/Oxford-BioMedica-to-Work-With-Microsoft-on-Gene-Therapy-Manufacturing-28148992/